Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $49000.0.

  • Artiva Biotherapeutics' Change in Receivables rose 13858.27% to $49000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$509000.0, marking a year-over-year increase of 6560.81%. This contributed to the annual value of -$1.0 million for FY2024, which is 24281.77% down from last year.
  • According to the latest figures from Q3 2025, Artiva Biotherapeutics' Change in Receivables is $49000.0, which was up 13858.27% from -$204000.0 recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Change in Receivables high stood at $88000.0 for Q1 2025, and its period low was -$888000.0 during Q4 2023.
  • Moreover, its 3-year median value for Change in Receivables was -$204000.0 (2025), whereas its average is -$229888.9.
  • As far as peak fluctuations go, Artiva Biotherapeutics' Change in Receivables plummeted by 5875.0% in 2024, and later soared by 14093.02% in 2025.
  • Artiva Biotherapeutics' Change in Receivables (Quarter) stood at -$888000.0 in 2023, then surged by 50.23% to -$442000.0 in 2024, then soared by 111.09% to $49000.0 in 2025.
  • Its Change in Receivables was $49000.0 in Q3 2025, compared to -$204000.0 in Q2 2025 and $88000.0 in Q1 2025.